ENTRY       D10843                      Drug
NAME        Alipogene tiparvovec (INN);
            Glybera (TN)
REMARK      ATC code: C10AX10
EFFICACY    Antihyperlipidemic
  DISEASE   Lipoprotein lipase deficiency (LPL S447X variant) [DS:H00154]
  TYPE      Gene therapy product
COMMENT     Adeno-associated virus serotype 1 (AAV1) vector carrying LPL [HSA:4023]
TARGET      LPL* [HSA_VAR:4023v1] [HSA:4023] [KO:K01059]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C10 LIPID MODIFYING AGENTS
               C10A LIPID MODIFYING AGENTS, PLAIN
                C10AX Other lipid modifying agents
                 C10AX10 Alipogene tiparvovec
                  D10843  Alipogene tiparvovec (INN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Carboxylic-ester hydrolases
                LPL* [HSA_VAR:4023v1]
                 D10843  Alipogene tiparvovec (INN)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10843
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10843
DBLINKS     CAS: 929881-05-0
            PubChem: 319902643
///
